Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR1A | P37288 | 3/20 | 0.40 |
| ▸ | TACR1 | P25103 | 4/20 | 0.38 |
| ▸ | AVPR2 | P30518 | 3/20 | 0.37 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.36 |
| ▸ | GPBAR1 | Q8TDU6 | 6/20 | 0.35 |
| ▸ | HTR2C | P28335 | 1/20 | 0.35 |
| ▸ | PDK1 | Q15118 | 2/20 | 0.35 |
| ▸ | PDK2 | Q15119 | 2/20 | 0.35 |
| ▸ | PDK3 | Q15120 | 2/20 | 0.35 |
| ▸ | PDK4 | Q16654 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5891002 | 0.91 | AVPR2 (0.44) | AVPR1AAVPR2ROCK2GPBAR1HTR2C | |
| SCHEMBL5891244 | 0.88 | AVPR2 (0.46) | AVPR1AAVPR2ROCK2HTR2CPDK1 | |
| SCHEMBL5890985 | 0.87 | AVPR1A (0.38) | AVPR1AAVPR2ROCK2GPBAR1 | |
| SCHEMBL3559762 | 0.87 | CYP1A2 (0.40) | AVPR2ROCK2 | |
| SCHEMBL5890952 | 0.86 | AVPR1A (0.39) | AVPR1ATACR1AVPR2 | |
| SCHEMBL5786364 | 0.86 | AVPR1A (0.44) | AVPR1AAVPR2 | |
| SCHEMBL5891612 | 0.85 | AVPR2 (0.46) | AVPR1ATACR1AVPR2ROCK2HTR2C | |
| SCHEMBL5891270 | 0.85 | AVPR2 (0.39) | AVPR1ATACR1AVPR2HTR2CPDK1 | |
| SCHEMBL5785027 | 0.84 | AVPR1A (0.42) | AVPR1AAVPR2 | |
| SCHEMBL5890921 | 0.84 | AVPR2 (0.51) | AVPR1AAVPR2ROCK2HTR2CPDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7064120-B2 | Tricyclic pyridyl carboxamides and derivatives thereof tocolytic oxytocin receptor antagonists | WYETH (US) | 2006-06-20 | — | — | US | claimed |
| WO-2002083683-A9 | NOVEL TRICYCLIC PYRIDYL BENZAZEPINE CARBOXAMIDES AND DERIVATIVES THEREOF TOCOLYTIC OXYTOCIN RECEPTOR ANTAGONISTS | WYETH CORP (US) | 2004-02-26 | — | — | WO | claimed |
| EP-1377581-A1 | NOVEL TRICYCLIC PYRIDYL BENZAZEPINE CARBOXAMIDES AND DERIVATIVES THEREOF AS TOCOLYTIC OXYTOCIN RECEPTOR ANTAGONISTS | Wyeth (US) | 2004-01-07 | — | — | EP | claimed |
| US-20030055047-A1 | Novel tricyclic pyridyl carboxamides and derivatives thereof tocolytic oxytocin receptor antagonists | WYETH | 2003-03-20 | — | — | US | claimed |
| WO-2002083683-A1 | NOVEL TRICYCLIC PYRIDYL BENZAZEPINE CARBOXAMIDES AND DERIVATIVES THEREOF TOCOLYTIC OXYTOCIN RECEPTOR ANTAGONISTS | WYETH (US) | 2002-10-24 | — | — | WO | claimed |
| US-7064120-B2 | Tricyclic pyridyl carboxamides and derivatives thereof tocolytic oxytocin receptor antagonists | WYETH (US) | 2006-06-20 | — | — | US | disclosed |
| WO-2002083683-A9 | NOVEL TRICYCLIC PYRIDYL BENZAZEPINE CARBOXAMIDES AND DERIVATIVES THEREOF TOCOLYTIC OXYTOCIN RECEPTOR ANTAGONISTS | WYETH CORP (US) | 2004-02-26 | — | — | WO | disclosed |
| EP-1377581-A1 | NOVEL TRICYCLIC PYRIDYL BENZAZEPINE CARBOXAMIDES AND DERIVATIVES THEREOF AS TOCOLYTIC OXYTOCIN RECEPTOR ANTAGONISTS | Wyeth (US) | 2004-01-07 | — | — | EP | disclosed |
| US-20030055047-A1 | Novel tricyclic pyridyl carboxamides and derivatives thereof tocolytic oxytocin receptor antagonists | WYETH | 2003-03-20 | — | — | US | disclosed |
| WO-2002083683-A1 | NOVEL TRICYCLIC PYRIDYL BENZAZEPINE CARBOXAMIDES AND DERIVATIVES THEREOF TOCOLYTIC OXYTOCIN RECEPTOR ANTAGONISTS | WYETH (US) | 2002-10-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030055047-A1 | Novel tricyclic pyridyl carboxamides and derivatives thereof tocolytic oxytocin receptor antagonists | OXTR, OPRL1, OPRK1 | AVPR1A 33/4885TACR1 164/4885AVPR2 70/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.